Screener
Avalo Therapeutics AVTX CapEx
Discontinued — last reported Q4 '24
CapEx at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForCapitalImprovements.
The source filing: Avalo Therapeutics’s 10-K, filed March 20, 2025.
- Filed
- Mar 20, 2025
- Fiscal year
- FY2024
- Accession
- 0001628280-25-013986
| Line item | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|
| Net cash used in operating activities | (49,056) | (30,680) |
| Investing activities | ||
| Cash assumed from AlmataBio Transaction | 356 | — |
| Leasehold improvements | — | (158) |
| Disposal of property and equipment | — | 25 |
| Net cash provided by (used in) investing activities | 356 | (133) |
| Financing activities | ||
| Proceeds from private placement investment, gross | 115,625 | — |
Item 16. Form 10-K Summary
FAQ
- What is Avalo Therapeutics's capex?
- Avalo Therapeutics (AVTX) reported capex of $0 in Q4 2024.
- What is the long-term trend for Avalo Therapeutics's capex?
- Over 2 years (2021 to 2024), Avalo Therapeutics's capex has grown at a -100.0% compound annual growth rate (CAGR), from $113K to $0.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Avalo Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude